Chemoenzymatic and Protecting-Group-Free Synthesis of 1,4-Substituted 1,2,3-Triazole-α-d-glucosides with Potent Inhibitory Activity toward Lysosomal α-Glucosidase. Jaggaiah N. Gorantla, Santhi Maniganda, Salila Pengthaisong, Lukana Ngiwsara, Phannee Sawangareetrakul, Suwadee Chokchaisiri, Prasat Kittakoop, Jisnuson Svasti, James R. Ketudat Cairns. ACS Omega. 2021 Sep 22;6(39):25710-25719.

22 Sep 2021
0
0

Chemoenzymatic and Protecting-Group-Free Synthesis of 1,4-Substituted 1,2,3-Triazole-α-d-glucosides with Potent Inhibitory Activity toward Lysosomal α-Glucosidase.

Jaggaiah N. Gorantla, Santhi Maniganda, Salila Pengthaisong, Lukana Ngiwsara, Phannee Sawangareetrakul, Suwadee Chokchaisiri, Prasat Kittakoop, Jisnuson Svasti, James R. Ketudat Cairns.

ACS Omega. 2021 Sep 22;6(39):25710-25719.

Tags

Share this

Related Posts

Identification of novel allergen in edible insect, Gryllus bimaculatus and its cross-reactivity with Macrobrachium spp. allergens. Srinroch C, Srisomsap C, Chokchaichamnankit D, Punyarit P, Phiriyangkul P*. Food Chem. 2015 Oct 1;184:160-6.
01 Oct 2015
0

Identification of novel allergen in edible insect, Gryllus bimaculatus and its cross-reactivity with Macrobrachium spp. allergens. Srinroch C, Srisomsap C, Chokchaichamnankit D, Punyarit P, Phiriyangkul P*. Food Chem. 2015 Oct 1;184:160-6.

Identification of novel allergen in edible insect, Gryllus bimaculatus and its cross-reactivity with Macrobrachium spp. allergens. Srinroch C,SrisomsapC, Chokchaichamnankit D, Punyarit P, Phiriyangkul P*. Food Chem. 2015 Oct 1;184:160-6.
View More

Recent Posts

Efficacy of Andrographis paniculata extract treatment in mild to moderate COVID-19 patients being treated with favipiravir: A double-blind, randomized, placebo-controlled study (APFaVi trial)
20 Sep 2023
0

Efficacy of Andrographis paniculata extract treatment in mild to moderate COVID-19 patients being treated with favipiravir: A double-blind, randomized, placebo-controlled study (APFaVi trial)

Efficacy of Andrographis paniculata extract treatment in mild to moderate COVID-19 patients being treated with favipiravir: A double-blind, randomized, placebo-controlled study (APFaVi trial) Siripongboonsitti T, Ungtrakul T, Tawinprai K, Auewarakul C, Chartisathian W, Jansala T, Julsawad R, Soonklang K, Mahanonda N, Mahidol C Phytomedicine. 2023;119:155018.
View More